Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in
A business owner researches how acid-test ratios are used. SmartAsset and Yahoo Finance LLC may earn commission or revenue through links in the content below. The acid-test ratio is a financial metric that assesses a company’s ability to cover short-term liabilities with its most liquid assets. A higher acid-test ratio suggests a stronger liquidity position,
Revenue: $5.9 million in Q4 2024, down from $6.7 million in Q4 2023. Operating Loss: $1.3 million in Q4 2024, compared to operating income of $0.1 million in Q4 2023. Net Loss: $1 million or $0.07 per share in Q4 2024, versus net income of $0.2 million or $0.01 per diluted share in Q4 2023.
Cash Equivalents and Marketable Securities: $245 million as of December 31, 2024, down from $314 million as of December 31, 2023. R&D Expenses: $209 million for the year ended December 31, 2024, compared to $232 million in 2023. Net Proceeds from Public Offering: $131 million received from an upsized public offering of common stock and
GH Research PLC Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track
Revenue: $148 million, up 4% year-over-year on an organic basis. Non-GAAP EPS: $0.08 per share. Adjusted EBITDA Margin: 9%, representing a 400 basis point expansion year-over-year. Free Cash Flow: $2 million for the quarter. Cash Position: $530 million in cash, cash equivalents, and marketable securities. Sample Management Solutions Revenue: $81 million, up 3% year-over-year. Multiomics
What is Nasdaq Cash, Cash Equivalents, Marketable Securities? Nasdaq‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 ($641.00 Mil) to Mar. 2024 ($561.00 Mil) but then increased from Mar. 2024 ($561.00 Mil) to Jun. 2024 ($590.00 Mil). Nasdaq‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($601.00 Mil) to Dec. 2022
What is Altice USA Cash, Cash Equivalents, Marketable Securities? Altice USA‘s quarterly cash, cash equivalents, marketable securities declined from Dec. 2023 (MXN5,127.21 Mil) to Mar. 2024 (MXN4,720.81 Mil) but then increased from Mar. 2024 (MXN4,720.81 Mil) to Jun. 2024 (MXN6,633.84 Mil). Altice USA‘s annual cash, cash equivalents, marketable securities increased from Dec. 2021 (MXN4,014.82 Mil)
What is Centrica Cash, Cash Equivalents, Marketable Securities? Centrica‘s quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (€7,972.53 Mil) to Dec. 2023 (€7,828.16 Mil) but then stayed the same from Dec. 2023 (€7,828.16 Mil) to Jun. 2024 (€7,506.46 Mil). Centrica‘s annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€5,442.99 Mil) to
What is Gamida Cell Cash, Cash Equivalents, Marketable Securities? Gamida Cell‘s quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($60.43 Mil) to Dec. 2023 ($46.55 Mil) but then stayed the same from Dec. 2023 ($46.55 Mil) to Mar. 2024 ($24.78 Mil). Gamida Cell‘s annual cash, cash equivalents, marketable securities declined from Dec. 2021